3rd Quarter - Report

VAN SCOYOC ASSOCIATES for UNIVERSITY OF PENNSYLVANIA SCHOOL OF MEDICINE

Firm
Client
Income
$40,000
Expenses
—

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Public Law 111-148, Patient Protection and Affordable Care Act (PPACA), Medicare Reimbursement; and Comparative Effectiveness Research. Monitor implementation of PPA Study on GME issues. Drug Safety issues Clinical Trial Reform issues FDA extramural research issues. Partnership for Patient Program issues. Graduate Medical Education funding issues. HOPPS Regulation, Proton theory issues.

LobbyistCovered position, as disclosed
KEVIN PATRICK KELLY —
KEVIN F KELLY —

Contacted: SENATE

Veterans VET

No lobbying activity.

LobbyistCovered position, as disclosed
KEVIN F KELLY —
KEVIN PATRICK KELLY —

Contacted: SENATE

Budget/Appropriations BUD

S.2375/H.R.5973, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2013, FDA funding initiatives. Public Law 111-148, Patient Protection and Affordable Care Act, Medicare Reimbursement; Comparative Effectiveness Research; Geographic Variation; and issues related to Academic Health Centers S.3295, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2013, Agency for Healthcare Research and Quality, Centers for Education and Research on Therapeutics (CERTS Center), NIH funding. Graduate Medical Education funding issues. Public Law 112-74, Consolidated Appropriations Act, FY2012, Agency for Healthcare Research and Quality, Centers for Education and Research on Therapeutics (CERTS Center), NIH funding. Public Law 112-55, Consolidated and Further Continuing Appropriations Act, FY2012, FDA funding initiatives. H.J.Res.117, Continuing Appropriations Resolution, FY2013, Sequestration issues.

LobbyistCovered position, as disclosed
KEVIN F KELLY —
KEVIN PATRICK KELLY —

Contacted: SENATE

Bills named: S. 3295 (112th), S. 2375 (112th), H.J.Res. 117 (112th), H.R. 5973 (112th)

Medicare/Medicaid MMM

Physician payment issues. Non-profit hospital regulations and oversight. Comparative effectiveness research.

LobbyistCovered position, as disclosed
KEVIN PATRICK KELLY —
KEVIN F KELLY —

Contacted: SENATE

Pharmacy PHA

FDA funding initiatives; Critical Path Partnership. S.2375/H.R.5973, Agriculture,Rural Development,Food and Drug Administration,and Related Agencies Appropriations Act, FY2013 Public Law 112-10, Department of Defense and Full-Year Continuing Appropriations Act, FY2011 Public Law 112-55, Consolidated and Further Continuing Appropriations Act, FY2012 Monitor Prescription Drug User Fee Act (PDUFA)

LobbyistCovered position, as disclosed
KEVIN F KELLY —
KEVIN PATRICK KELLY —

Contacted: SENATE

Bills named: S. 2375 (112th), H.R. 5973 (112th)

Medical/Disease Research/Clinical Labs MED

Public Law 111-148, Patient Protection and Affordable Care Act, Medicare Reimbursement; Comparative Effectiveness Research; and Federal Medical Assistance Payments (FMAP) issues. Federal Medical Assistance Payments (FMAP) legislation and tax extenders.

LobbyistCovered position, as disclosed
KEVIN F KELLY —
KEVIN PATRICK KELLY —

Contacted: SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.